Schneider-Hohendorf, Tilman
Mohan, Hema
Bien, Christian G.
Breuer, Johanna
Becker, Albert
Görlich, Dennis
Kuhlmann, Tanja
Widman, Guido
Herich, Sebastian
Elpers, Christiane
Melzer, Nico
Dornmair, Klaus
Kurlemann, Gerhard
Wiendl, Heinz
Schwab, Nicholas
Article History
Received: 23 December 2015
Accepted: 25 February 2016
First Online: 4 April 2016
Competing interests
: N.S. received honoraria for advisory boards and travel expenses from Biogen Idec. T.S.-H. received travel expenses compensation from Biogen Idec. H.W. received honoraria and consultation fees from Bayer Healthcare, Biogen Idec, Fresenius Medical Care, GlaxoSmithKline, GW Pharmaceuticals, Merck Serono, Novartis Pharma, Sanofi Genzyme and TEVA Pharma. G.K. received honoraria for scientific advisory boards of UCB, Shire, Eisai and Viropharma; he received honoraria for speaking engagements from Desitin, Eisai, Viropharma, UCB, Dibropharma, Novartis, Biogen, Shire. T.K. received speaker honoraria from Novartis, Biogen Idec Canada and Teva; she received compensation as a consultant from Genzyme. C.E. has received honoraria for lecturing and travel expenses for attending meetings from Bayer, Biogen Idec and Sanofi-Aventis. C.G.B. gave scientific advice to Eisai and UCB, undertook industry-funded travel with support of Eisai, UCB, Desitin, and Grifols, obtained honoraria for speaking engagements from Eisai, UCB, Desitin, diamed, Fresenius Medical Care, and received research support from diamed and Fresenius Medical Care. He is a consultant to the Laboratory Krone, Bad Salzuflen, Germany, regarding antineural antibodies. N.M. has received honoraria for lecturing and travel expenses for attending meetings from Biogen Idec, GlaxoSmithKline, Teva, Novartis Pharma, Bayer Healthcare and Fresenius Medical Care and has received financial research support from Fresenius Medical Care.